Brovana Approval History
FDA Approved: Yes (First approved October 6, 2006)
Brand name: Brovana
Generic name: arformoterol tartrate
Dosage form: Inhalation Solution
Company: Sepracor Inc.
Treatment for: COPD
Brovana (arformoterol tartrate) is a long-acting beta2-agonist for inhalation via a nebulizer, used for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Development History and FDA Approval Process for Brovana
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.